UnitedHealth Group (NYSE:UNH) Price Target Raised to $390.00 at Bank of America

Key Points

• Bank of America has raised its price target for UnitedHealth Group (NYSE:UNH) from $350.00 to $390.00, indicating a potential upside of 5.24% from the current price.
• The company currently holds a consensus rating of "Hold" among analysts, with a consensus target price of $372.68.
• UnitedHealth Group's earnings results revealed an EPS of $4.08 for the last quarter, missing the consensus estimate by $0.37, despite a 12.9% year-over-year revenue increase.

UnitedHealth Group (NYSE:UNH - Get Free Report) had its target price lifted by research analysts at Bank of America from $350.00 to $390.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a "neutral" rating on the healthcare conglomerate's stock. Bank of America's price target points to a potential upside of 5.24% from the company's current price.

UNH has been the topic of a number of other research reports. UBS Group restated a "buy" rating on shares of UnitedHealth Group in a report on Thursday, July 17th. KeyCorp upped their price target on shares of UnitedHealth Group from $350.00 to $400.00 and gave the stock an "overweight" rating in a research note on Wednesday. Truist Financial upped their price target on shares of UnitedHealth Group from $310.00 to $365.00 and gave the stock a "buy" rating in a research note on Tuesday, September 9th. JPMorgan Chase & Co. dropped their price target on shares of UnitedHealth Group from $418.00 to $310.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 6th. Finally, Baird R W lowered UnitedHealth Group from a "hold" rating to a "strong sell" rating in a research report on Thursday, July 31st. Sixteen investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and four have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, UnitedHealth Group currently has a consensus rating of "Hold" and a consensus target price of $372.68.

UnitedHealth Group Price Performance

Shares of UNH stock traded up $6.92 during trading hours on Wednesday, hitting $370.58. 8,164,734 shares of the company's stock were exchanged, compared to its average volume of 12,738,613. The company has a market capitalization of $335.62 billion, a PE ratio of 16.08, a PEG ratio of 2.33 and a beta of 0.47. UnitedHealth Group has a 12-month low of $234.60 and a 12-month high of $630.73. The business's 50 day simple moving average is $311.44 and its 200-day simple moving average is $352.42. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 0.73.

UnitedHealth Group (NYSE:UNH - Get Free Report) last issued its earnings results on Tuesday, July 29th. The healthcare conglomerate reported $4.08 EPS for the quarter, missing the consensus estimate of $4.45 by ($0.37). The firm had revenue of $111.62 billion during the quarter, compared to analysts' expectations of $111.75 billion. UnitedHealth Group had a return on equity of 23.32% and a net margin of 5.04%.The firm's quarterly revenue was up 12.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $6.80 earnings per share. UnitedHealth Group has set its FY 2025 guidance at 16.000- EPS. On average, equities research analysts anticipate that UnitedHealth Group will post 29.54 earnings per share for the current year.

Institutional Trading of UnitedHealth Group

Institutional investors and hedge funds have recently made changes to their positions in the company. Citizens National Bank Trust Department raised its holdings in shares of UnitedHealth Group by 1.0% in the first quarter. Citizens National Bank Trust Department now owns 17,886 shares of the healthcare conglomerate's stock valued at $9,368,000 after acquiring an additional 170 shares in the last quarter. Fort Washington Investment Advisors Inc. OH grew its stake in UnitedHealth Group by 0.3% in the first quarter. Fort Washington Investment Advisors Inc. OH now owns 530,103 shares of the healthcare conglomerate's stock valued at $277,641,000 after purchasing an additional 1,465 shares during the last quarter. Caitlin John LLC grew its stake in UnitedHealth Group by 14.8% in the first quarter. Caitlin John LLC now owns 862 shares of the healthcare conglomerate's stock valued at $451,000 after purchasing an additional 111 shares during the last quarter. Triumph Capital Management purchased a new position in UnitedHealth Group in the second quarter valued at about $1,324,000. Finally, Wealth Effects LLC grew its stake in UnitedHealth Group by 14.4% in the second quarter. Wealth Effects LLC now owns 4,688 shares of the healthcare conglomerate's stock valued at $1,463,000 after purchasing an additional 591 shares during the last quarter. 87.86% of the stock is currently owned by institutional investors.

About UnitedHealth Group

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.